
In veterinary pharmacovigilance, failure to work is not just a quality complaint. When a medicine does not deliver the expected effect despite correct use, it[…]

A vaccine is not a pharmaceutical with an antigen instead of a chemical. Its quality, safety and efficacy evidence, the way it is released and[…]

Autogenous vaccines are made from the pathogens of a specific herd and used in that herd. Regulation (EU) 2019/6 allows them outside the marketing authorisation[…]

A generic veterinary medicine can rely on the reference product’s data, but only if it truly behaves like a generic. When it does not, Regulation[…]

Veterinary pharmacovigilance covers much more than an animal that reacts badly to a product. Under Regulation (EU) 2019/6, the Union Pharmacovigilance Database is the single[…]

Under Regulation (EU) 2019/6, spotting a safety signal is no longer an informal exercise. Marketing authorisation holders (MAHs), national authorities and EMA share the job,[…]

Homeopathic veterinary medicines can reach the market through a simplified registration rather than a full marketing authorisation. Regulation (EU) 2019/6 sets firm boundaries, and products[…]

Anyone who manufactures, finishes, tests, releases or imports veterinary medicines in the EU needs a manufacturing authorisation. Regulation (EU) 2019/6 defines the scope broadly, and[…]

Regulation (EU) 2019/6 gives parallel trade in veterinary medicines a clear legal basis for the first time at EU level. Article 102 sets the conditions,[…]

Promotion of veterinary medicines is tightly bounded by Regulation (EU) 2019/6. Article 119 sets the conditions for what may be advertised, how, and what may[…]